In another aspect, the present invention is direct to the use of a compound or composition as defined herein, and optionally a molecule to be internalized in the manufacture of a medicament for treating or preventing a disease, disorder or infection in a patient, wherein said disease, disorder or infection is selected from the group consisting of cancer, benign tumours, actinic keratosis, warts, moles, HIV, influenza, canine parvovirus, bovine leukaemia virus, hepatitis and multiple sclerosis; wherein preferably said medicament is for use as a vaccine..

In another aspect, the present invention is direct to a kit comprising a compound or composition as defined herein and a molecule to be internalized, preferably for simultaneous, separate or sequential use to treat or prevent a disease, disorder or infection in a subject, preferably for use in therapy, preferably cancer therapy, gene therapy or for stimulating an immune response.

10. An *in vitro* method for introducing a molecule into the cytosol of a cell, comprising contacting said cell with the molecule to be introduced and a compound as defined in any one of claims 1 to 9, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent of the compound thereby releasing the molecule into the cytosol.

11. An *in vitro* method of achieving death of a cell comprising contacting said cell with a compound as defined in any one of claims 1 to 9, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent of the compound to generate reactive oxygen species which cause death of said cell.

12. An *in vitro* method of expressing an antigenic molecule or a part thereof on the surface of a cell, comprising contacting said cell with said antigenic molecule and a compound as defined in any one of claims 1 to 9, and irradiating the cell with light of a wavelength effective to activate the photosensitising agent of the compound, wherein said antigenic molecule is released into the cytosol of the cell and the antigenic molecule or a part thereof of sufficient size to stimulate an immune response is presented on the cell's surface.

13. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 9 and one or more pharmaceutically acceptable diluents, carriers or excipients, and optionally a molecule to be internalized.

14. A compound or composition as defined in any one of claims 1 to 9 and 13, and optionally a molecule to be internalised, for use in therapy.

15. A cell or a population of cells obtained by a method as defined in any one of claims 10 to 12.

16. The cell or population of cells as claimed in claim 15 for use in therapy, preferably for cancer therapy, gene therapy or for stimulating an immune response.

17. Use of a compound or composition as defined in any one of claims 1 to 9 and 13, and optionally a molecule to be internalized in the manufacture of a medicament for treating or preventing a disease, disorder or infection in a patient, wherein said disease, disorder or infection

is selected from the group consisting of cancer, benign tumours, actinic keratosis, warts, moles, HIV, influenza, canine parvovirus, bovine leukaemia virus, hepatitis and multiple sclerosis; wherein preferably said medicament is for use as a vaccine.

18. The use of claim 17, wherein said cancer is head and neck cancer, cancer of the bile duct, brain cancer, melanoma, skin metastases, lung cancer, mesothelioma, pancreatic cancer, gastric cancer, rectal cancer, anal cancer, penis cancer, vulva cancer or oesophageal cancer.

19. The use according to claim 17 or 18, wherein said treatment or prevention is to comprise that cells in the patient are to be contacted with said medicament, and that the cells are to be irradiated with light of a wavelength effective to activate the photosensitising agent of the compound.

20. The use according to claim 19, wherein said molecule to be internalized is a cytotoxic molecule.

21. The use according to claim 20, wherein said cytotoxic molecule is bleomycin.

22. The use according to claim 17 or 18, wherein said medicament is for treating cancer, benign tumours, actinic keratosis, warts or moles, and said treatment is to comprise that cells in the patient are to be contacted with said medicament, and that the cells are to be irradiated with light of a wavelength effective to activate the photosensitising agent of the compound to generate reactive oxygen species which cause death of said cells.

23. A kit comprising a compound or composition as defined in any one of claims 1 to 9 and 13 and a molecule to be internalized, preferably for simultaneous, separate or sequential use to treat or prevent a disease, disorder or infection in a subject, preferably for use in therapy, preferably cancer therapy, gene therapy or for stimulating an immune response.